Myeloproliferative neoplasms (MPNs), encompassing disorders like polycythemia vera (PV),
essential thrombocythemia (ET), and primary myelofibrosis (PMF), are characterized by …

Polycythemia vera (PV) and essential thrombocythemia (ET) constitute two of the three BCR-
ABL1-negative myeloproliferative neoplasms and are characterized by relatively long …

The Philadelphia-negative chronic myeloproliferative neoplasms (MPNs) are acquired stem
cell neoplasms, in which a stem cell lesion induces an autonomous proliferative advantage …

We report the final 2-year end-of-study results from the first clinical trial investigating
combination treatment with ruxolitinib and low-dose pegylated interferon-α2 (PEG-IFNα2) …

Background Pegylated interferon alfa-2a is an immunomodulatory agent used to treat
polycythemia vera. The durability of responses and long-term safety of this drug in patients …

Myelofibrosis (MF) is a life-threatening blood cancer characterized by progressive bone
marrow fibrosis, splenomegaly, cytopenias, and debilitating constitutional symptoms …

Data on the efficacy and safety of interferon (IFN)-α for the treatment of essential
thrombocythemia (ET) and polycythemia vera (PV) are inconsistent. We conducted a …

Chronic myeloproliferative neoplasms (MPN) are stem cell disorders driven by mutations in
JAK2, CALR, or MPL genes and characterized by myeloid proliferation and increased blood …

Recombinant IFN-α (rIFN-α) induces complete hematologic remissions in patients with
myeloproliferative neoplasms (MPNs), but its use has been limited by side effects owing to …

Interferon-based therapies, such as ropeginterferon alfa-2b have emerged as promising
disease-modifying agents for myeloproliferative neoplasms (MPNs), including essential …